Gyre Therapeutics announced positive results from its Phase 3 trial of Hydronidone, a treatment for liver fibrosis in patients with chronic hepatitis B (CHB), showing a significant regression in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results